EUCTR2012-005404-17-DK进行中（未招募）1 期
Treatment of antipsychotic associated obesity with a GLP-1 Analogue: the TAO study - Treatment of antipsychotic associated obesity
Center for Neuropsychiatric Schizophrenia Research0 个研究点目标入组 45 人开始时间: 2013年1月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age: 18 - 65 years
- •Diagnosis in the schizophrenic spectrum (ICD-10: F20.x, F25.x)
- •Treatment with a least one antipsyhcotic agent (FGS/SGA) for a least 3 months
- •BMI = 30 kg/m2
- •HbA1c < 6,5 %
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Active abuse of psychoactive drugs (ICD-10: F1x.2 (not nicotine))
- •Contradictions to MRI (metalimplant, pacemaker, claustrofobia, =150 kg (max. weight in the MR scanner))
- •Former headtrauma with loss of conciousness more than 5 minutes
- •Severe medical condition/illness
- •Allergi towards exenatide (Bydureon®)
- •Suicidality
- •Forensic psychiatry patient
- •Conditions, who according to Sponsor or Invesigator are not fit for joining the investigation
研究者
相似试验
招募中
不适用
Physical activity for adults with serious mental illness.Physical inactivityPhysical Medicine / Rehabilitation - Other physical medicine / rehabilitationMental Health - SchizophreniaSchizophreniaACTRN12612000291886Julie Ayliffe10
已完成
3 期
Treatment of Antipsychotic-associated Obesity With a GLP-1 AnalogueMetabolic Syndrome XDrug-induced ObesityObesitySchizophreniaNCT01794429Bjorn H. Ebdrup45
已完成
不适用
Matched treatment of obesity in overweight patients. A randomised controlled trial. (pilot is non-randomised treatment-control study. This ABR application pertains to the pilot study)overgewichtobesity and eating disorders10014067NL-OMON31706GGZ Oost Brabant (Rosmalen)50
进行中（未招募）
Unknown
How genetics, behaviour, and environment can contribute to a condition called metabolic syndrome in people who are taking antipsychotic medicatioGenetic, behavioural and environmental risk factors of metabolic syndrome in people treated with antipsychotics (schizophrenia, bipolar disorder, neurodevelopmental disorder)Mental and Behavioural DisordersISRCTN18419418Ministero della Salute75
已完成
不适用
ew approach for obesity treatment incorporating individual self-management educatioObesityJPRN-UMIN000009608niversity of Tsukuba28